Clinical Trials Directory

Trials / Completed

CompletedNCT02537743

Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma

Open-labeled, Multicenter, Non-interventional, Prospective PRO Registry for Patients With First Line Treatment for Advanced RCC Using a Tablet-technology Based Digital Device

Status
Completed
Phase
Study type
Observational
Enrollment
98 (actual)
Sponsor
iOMEDICO AG · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Evaluation of patient reported outcomes ( PRO) regarding typical ailments in the REAL LIFE Renal Cell Carcinoma population

Detailed description

The PRO Kidney project will recruit a representative cohort of patients with advanced renal cell carcinoma (RCC) treated with systemic antiproliferative therapies such as TKIs, mTOR inhibitors, cytokines, antiVEGF or immune therapy. The aim of this study is to collect data on the effectiveness and patients´quality of life on preference in the real life setting. Patient Reported Outcomes ( PRO) are assessed by a questionnaire consisting Functional Assessment of Cancer Therapy ( FACT) Kidney Syndrome Index 19 (FKSI 19) completed by four questions assessing ailments about changes in skin of hands/feet, taste, color of hair and mouth scores. 13 Questions about Fatigue assessed with the Functional Assessment of Chronic IIlness Disease.

Conditions

Timeline

Start date
2015-08-19
Primary completion
2021-02-19
Completion
2021-02-19
First posted
2015-09-02
Last updated
2021-03-25

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT02537743. Inclusion in this directory is not an endorsement.

Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma (NCT02537743) · Clinical Trials Directory